Equity Overview
Price & Market Data
Price: $0.95
Daily Change: -$0.03 / 3.16%
Range: $0.95 - $1.00
Market Cap: $34,719,460
Volume: 28,885
Performance Metrics
1 Week: -7.77%
1 Month: -10.38%
3 Months: -31.16%
6 Months: -4.51%
1 Year: -22.76%
YTD: -26.36%
Company Details
Employees: 10
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.